Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAG-MS: NLY01 for Multiple Sclerosis
NCT07497399Phase 2Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Apr 2026
- Primary completion
- Jan 2030
- Modality
- Polymer-based Nanoparticles, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pegsebrenatide in multiple sclerosis (MS), sponsored by Johns Hopkins University. Started Apr 2026; status: recruiting.
02
Drugs
pegsebrenatide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07497399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497399.